Cerebral Palsy (CP)
Cerebral Palsy is a devastating brain disorder that affects many children worldwide with 10,000 infants diagnosed annually. CP is acquired at an early age, usually less than a year of age.
Umbilical cord MSCs have shown promise in the treatment of Cerebral Palsy (CP) in both animal models and early human trials. In one of the studies conducted at Monash University Medical School, Johor Bahru, Malaysia, autologous UCB seems to be feasible and safe with encouraging functional outcome improvements in two children with CP. They were reclassified as GMFCS level I, up from level III after transplantation indicating improvement in intellectual quotient (IQ). Recently, considerable excitement has been generated by reports of improvement after umbilical cord tissue stem cell infusions in children treated in a clinical study. This treatment has been used to treat more than 50 children with CP. Preliminary observations have been encouraging.
Case Report
- Positron Emission Tomography-Computed Tomography Scan Captures the Effects of Cellular Therapy in a Case of Cerebral Palsy
- Safety and feasibility of autologous umbilical cord blood transfusion in 2 toddlers with cerebral palsy and the role of low dose granulocytecolony stimulating factor injections
- The Levels of Pro-Inflammatory Factors Are Significantly Decreased in Cerebral Palsy Patients Following an Allogeneic Umbilical Cord Blood Cell Transplant
- First Autologous Cell Therapy of Cerebral Palsy Caused by Hypoxic-Ischemic Brain Damage in a Child after Cardiac Arrest—Individual Treatment with Cord Blood